在泰国癌症患者中,EPHX1和ERCC2多态与西斯普拉丁诱导的毒性和预后有关
Saad Ahmed1, Jakris Eu-Ahsunthornwattana2,3, Thanaporn Thamrongjirapat4
1Program in Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
PloS one
|June 17, 2025
概括
药物代谢和DNA修复基因的遗传变异与泰国癌症患者中西斯胺诱导的损伤有关. EPHX1 rs1051740与急性病相关,而ERCC2 SNPs影响整体存活率,有助于预测患者易感性.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 西斯是治疗各种癌症的关键化疗剂.
- 西斯普拉丁诱导的毒性 (CIN),包括急性损伤 (AKI) 和急性病 (AKD),是显著的不良影响.
- 单核酸多态 (SNP) 可以识别患有CIN.风险的患者.
研究的目的:
- 在泰国癌症患者中验证特定SNP在药物代谢 (SLC22A2,EPHX1) 和DNA修复 (ERCC1,ERCC2) 基因和CIN之间的关联.
- 评估这些SNP对AKD发病率,无进展生存期 (PFS) 和整体生存期 (OS) 的影响.
主要方法:
- 在169名泰国头,肺或食道癌患者中,对6个SNP (SLC22A2 rs316019,EPHX1 rs1051740,ERCC1 rs11615 & rs3212986,ERCC2 rs13181 & rs1799793) 的基因定型.
- 统计分析以评估SNP与CIN之间的关联,AKD累积发病率,PFS和OS.
主要成果:
- 在共占优势和超占优势的模型中,EPHX1 rs1051740 TC基因型与AKD显著相关,并增加了AKD累积发病率.
- ERCC2 SNPs rs13181和rs1799793显示出与整体存活时间 (OS) 有显著的关联.
- 这些发现证实了之前报告的ERCC2SNP和OS之间的关联.
结论:
- 在这个泰国队列中发现了EPHX1 rs1051740和AKD之间的关联.
- 这项研究证实了ERCC2SNP与癌症患者的OS之间的联系.
- 这些遗传标记可能有助于预测泰国癌症患者中西斯普拉丁诱导的毒性风险.
相关概念视频
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K